- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1198151-75-5] Vapendavir diphosphate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-106254A |
| Brand: | MCE |
| CAS: | 1198151-75-5 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 578.45 |
| Molecular Formula | C21H32N4O11P2 |
| SMILES | CCOC1=NOC2=CC(OCCC3CCN(C4=CC=C(C)N=N4)CC3)=CC=C12.OP(O)(O)=O.OP(O)(O)=O |
1 Publications Citing Use of MCE
Summary
Vapendavir diphosphate (BTA798 diphosphate) is a potent enteroviral capsid binder (CB). Vapendavir diphosphate (BTA798 diphosphate) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC 50 values of 0.5-1.4 μM in different EV71 strains [1] [2] .
In Vitro
Vapendavir (BTA798) efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03024177 | Vaxart |
Rhinovirus|Upper Respiratory Tract Infection
|
Phase 2 | |
| NCT02877264 | Aviragen Therapeutics|Vaxart |
Healthy
|
June 2016 | Phase 1 |
| NCT02367313 | Biota Pharmaceuticals, Inc.|Vaxart |
Asthma
|
February 2015 | Phase 2 |
| NCT02101866 | Biota Pharmaceuticals, Inc.|Vaxart |
Healthy
|
March 2014 | Phase 1 |
| NCT02204501 | Biota Scientific Management Pty Ltd|Vaxart |
Drug-Drug Interaction Healthy Volunteers
|
May 2014 | Phase 1 |
| NCT01175226 | Biota Scientific Management Pty Ltd|Vaxart |
Rhinovirus
|
August 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 6.75 mg/mL ( 11.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7288 mL | 8.6438 mL | 17.2876 mL |
| 5 mM | 0.3458 mL | 1.7288 mL | 3.4575 mL |
| 10 mM | 0.1729 mL | 0.8644 mL | 1.7288 mL |
References
- [1] Tijsma A, et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2.
- [2] Sun L, et al. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.